Mark Currie Buys 63,481 Shares of Ironwood Pharmaceuticals
Ironwood Pharmaceuticals insider Mark Currie acquired 63,481 shares on June 16, 2026.
Key Points
- Mark Currie bought 63,481 shares of Ironwood Pharmaceuticals on June 16, 2026, with shares trading at $3.66.
- Ironwood Pharmaceuticals has a market cap of $579.4 million, a P/E ratio of 5.68, and a 52-week high of $5.78.
- Analysts have varied views, with Citizens rating it a 'buy' and setting a $10 target on February 26, 2026.
On June 16, 2026, Mark Currie, an insider at Ironwood Pharmaceuticals, Inc. (NasdaqGS: IRWD), bought 63,481 shares. The shares traded at $3.66 at the time of the transaction.
Insider Buying and Selling at Ironwood Pharmaceuticals, Inc.
Several insiders, including Shepard Jay, Marla Kessler, Alexander Denner, Catherine Moukheibir, Jon Duane, and Julie McHugh, each acquired 63,481 shares of Ironwood Pharmaceuticals on June 16, 2026. These transactions were not planned under Rule 10b5-1 plans.
Other Institutional Activity in Ironwood Pharmaceuticals
Ironwood Pharmaceuticals saw varied institutional activity. Armistice Capital, LLC reduced its holdings by 997,000 shares, leaving it with 15,028,000 shares valued at about $52.7 million. BlackRock, Inc. increased its stake by 578,124 shares, resulting in 13,362,930 shares worth approximately $46.9 million. Sarissa Capital Management LP significantly cut its position by 6,730,800 shares, holding 9,188,635 shares valued at around $32.3 million. Bank of America Corp /DE/ also reduced its holdings by 2,838,753 shares, ending with 8,682,907 shares valued at $30.5 million.
Ironwood Pharmaceuticals Stock Snapshot
Shares of Ironwood Pharmaceuticals (NasdaqGS: IRWD) traded near $3.66. The company has a market cap of $579.4 million and a P/E ratio of 5.68. The stock has a 52-week range of $0.66 to $5.78, with a 50-day moving average of $3.86 and a 200-day moving average of $3.25. Ironwood's beta is 0.241, indicating lower volatility compared to the market.
Recent Earnings
Ironwood Pharmaceuticals reported revenue of $361.5 million, with a growth rate of 1.6%. The company achieved a net margin of 28.3% and an EPS of $0.62. The next earnings report is scheduled for August 6, 2026.
Analysts Set New Price Targets
On February 26, 2026, Citizens maintained a 'buy' rating on Ironwood Pharmaceuticals, setting a price target of $10. Wells Fargo, on January 5, 2026, maintained a 'hold' rating with a $5 target. The consensus among analysts is a 'buy' rating, with a mean target price of $6.10 based on four opinions.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc. is a biotechnology company based in Boston, Massachusetts. It focuses on developing and selling treatments for gastrointestinal and rare diseases. Its products include linaclotide, marketed under the names LINZESS and CONSTELLA, for irritable bowel syndrome and chronic constipation. The company is also working on treatments for visceral pain conditions and short bowel syndrome. Ironwood collaborates with companies like AbbVie, AstraZeneca, and Astellas Pharma.
Bottom Line
Mark Currie's purchase of Ironwood Pharmaceuticals shares adds to the ongoing insider activity at the company. Ironwood's stock, with a low P/E ratio and recent insider buys, may attract attention as it prepares for its next earnings report in August. Investors monitor such insider transactions for potential insights, although these actions do not necessarily predict future stock performance.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.